{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:51:50Z","timestamp":1791273110702,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Normal tissue in a tumor-bearing organ shows morphological and molecular differences from normal tissue in a tumor-free organ. One explanation to this is that tumors actively instruct adjacent normal tissues to support growth and invasion. The aim of this study was to examine if changes in gene-expression patterns in tumor-adjacent histologically benign prostate tissue, termed tumor instructed normal tissue (TINT), were associated with tumor proximity, grade and molecular subtype and, furthermore, whether they could indicate the presence of high-grade cancer elsewhere in the prostate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Gene-expression analysis using Clariom D microarrays was performed on matched formalin-fixed paraffin-embedded samples including tumor tissue (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944), benign prostate tissue taken near (TINT-N,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944) or distant (TINT-D,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200942) to the tumor in 44 men with unifocal cancer treated by prostatectomy. TINT changes related to cell proliferation and immune cell infiltration were examined using immunohistochemical markers. In addition, gene expression was compared between tumor-negative biopsies from men later diagnosed with high-grade cancer (Bx-later-tumor,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946), tumor-negative biopsies from men who remained cancer-free (Bx-control,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200949), and cancer-containing biopsies (Bx-tumor,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928). Gene set enrichment analysis (GSEA) was performed to explore hallmark gene sets in tumor and TINT tissue in relation to tumor grade (high vs. low) and molecular subtype (Luminal B vs. Luminal A).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The transcriptome in TINT differed significantly from that in cancer-free biopsy control tissue and was related to tumor grade (high- vs. low), molecular subtype (Luminal B vs. Luminal A), and tumor proximity (TINT-N vs. TINT-D). Hallmarks related to cell proliferation and increased Ki67 staining as well as signs of increased metabolism were generally enriched in both tumor and TINT tissue of high grade and Luminal B tumors. In contrast, some immune responses were unique to TINT areas of high-grade and Luminal A tumors, respectively, and more obvious in TINT-N than in TINT-D. Analysis of Bx-later-tumor indicated enriched metabolism compared to Bx-control, without clear proliferative or immunological differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TINT effects involving proliferation, metabolism and immune responses are related to distance, tumor grade and molecular subtype. TINT alterations hold potential as diagnostic and prognostic biomarkers and may provide a basis for further exploration of tumor-host interactions and potential targets for intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-09035-8","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:43:46Z","timestamp":1791045826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene expression profiles in benign prostate tissue reflect tumor proximity, grade, and molecular subtype"],"prefix":"10.1186","volume":"24","author":[{"given":"Pernilla","family":"Wikstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Freyhult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Semenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lundholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Josefsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Halin","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-5821","authenticated-orcid":false,"given":"Anders","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"1","key":"9035_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s41467-017-01027-z","volume":"8","author":"D Aran","year":"2017","unstructured":"Aran D, Camarda R, Odegaard J, Paik H, Oskotsky B, Krings G, et al. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat CommunicationsNat Commun. 2017;8(1):1077. https:\/\/doi.org\/10.1038\/s41467-017-01027-z.","journal-title":"Nat CommunicationsNat Commun"},{"issue":"1","key":"9035_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1517\/17530059.2011.540009","volume":"5","author":"S Halin","year":"2011","unstructured":"Halin S, Hammarsten P, Adamo H, Wikstrom P, Bergh A. Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer. Expert Opin Med Diagn. 2011;5(1):37\u201347. https:\/\/doi.org\/10.1517\/17530059.2011.540009.","journal-title":"Expert Opin Med Diagn"},{"issue":"13","key":"9035_CR3","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/pros.20983","volume":"69","author":"L Nonn","year":"2009","unstructured":"Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate. 2009;69(13):1470\u201379. https:\/\/doi.org\/10.1002\/pros.20983.","journal-title":"Prostate"},{"issue":"10","key":"9035_CR4","doi-asserted-by":"publisher","first-page":"11960","DOI":"10.1002\/cam4.5864","volume":"12","author":"E Oh","year":"2023","unstructured":"Oh E, Lee H. Transcriptomic data in tumor-adjacent normal tissues harbor prognostic information on multiple cancer types. Cancer Med. 2023;12(10):11960\u201370. https:\/\/doi.org\/10.1002\/cam4.5864.","journal-title":"Cancer Med"},{"issue":"5","key":"9035_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q","volume":"6","author":"DP Slaughter","year":"1953","unstructured":"Slaughter DP, Southwick HW, Smejkal W. \u201cField cancerization\u201d in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 1953;6(5):963\u201368. https:\/\/doi.org\/10.1002\/1097-0142(195309)6:5%3C963::AID-CNCR2820060515%3E3.0.CO;2-Q.","journal-title":"Cancer"},{"key":"9035_CR6","doi-asserted-by":"publisher","unstructured":"Adamo HH, Stromvall K, Nilsson M, Halin Bergstrom S, Bergh A. Adaptive (TINT) changes in the tumor bearing organ are related to prostate tumor size and aggressiveness. PLoS One. 2015;10(11):e0141601. https:\/\/doi.org\/10.1371\/journal.pone.0141601.","DOI":"10.1371\/journal.pone.0141601"},{"key":"9035_CR7","doi-asserted-by":"publisher","unstructured":"Stromvall K, Thysell E, Halin Bergstrom S, Bergh A. Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis. PLoS One. 2017;12(5):e0176679. https:\/\/doi.org\/10.1371\/journal.pone.0176679.","DOI":"10.1371\/journal.pone.0176679"},{"issue":"5","key":"9035_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/pros.23749","volume":"79","author":"H Adamo","year":"2019","unstructured":"Adamo H, Hammarsten P, Hagglof C, Dahl Scherdin T, Egevad L, Stattin P, et al. Prostate cancer induces C\/EBP\u03b2 expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome. Prostate. 2019;79(5):435\u201345. https:\/\/doi.org\/10.1002\/pros.23749.","journal-title":"Prostate"},{"key":"9035_CR9","doi-asserted-by":"publisher","unstructured":"Adamo HH, Halin Bergstrom S, Bergh A. Characterization of a gene expression signature in normal rat prostate tissue induced by the presence of a tumor elsewhere in the organ. PLoS One. 2015;10(6):e0130076. https:\/\/doi.org\/10.1371\/journal.pone.0130076.","DOI":"10.1371\/journal.pone.0130076"},{"issue":"4","key":"9035_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/pros.23466","volume":"78","author":"SH Bergstr\u00f6m","year":"2018","unstructured":"Bergstr\u00f6m SH, J\u00e4remo H, Nilsson M, Adamo HH, Bergh A. Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness. Prostate. 2018;78(4):257\u201365. https:\/\/doi.org\/10.1002\/pros.23466.","journal-title":"Prostate"},{"issue":"4","key":"9035_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/path.5604","volume":"253","author":"S Halin Bergstrom","year":"2021","unstructured":"Halin Bergstrom S, Rudolfsson S, Lundholm M, Josefsson A, Wikstrom P, Bergh A. High-grade tumours promote growth of other less-malignant tumours in the same prostate. The J Pathol. 2021;253(4):396\u2013403. https:\/\/doi.org\/10.1002\/path.5604.","journal-title":"The J Pathol"},{"issue":"2","key":"9035_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2353\/ajpath.2010.100070","volume":"177","author":"A Johansson","year":"2010","unstructured":"Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010;177(2):1031\u201341. https:\/\/doi.org\/10.2353\/ajpath.2010.100070.","journal-title":"Am J Pathol"},{"issue":"4","key":"9035_CR13","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.ajpath.2011.06.005","volume":"179","author":"A Josefsson","year":"2011","unstructured":"Josefsson A, Adamo H, Hammarsten P, Granfors T, Stattin P, Egevad L, et al. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome. Am J Pathol. 2011;179(4):1961\u201368. https:\/\/doi.org\/10.1016\/j.ajpath.2011.06.005.","journal-title":"Am J Pathol"},{"key":"9035_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmolb.2025.1426949","volume":"12","author":"I Dudka","year":"2025","unstructured":"Dudka I, Figueira J, Wikstr\u00f6m P, Bergh A, Gr\u00f6bner G. Metabolic readouts of tumor instructed normal tissues (TINT) identify aggressive prostate cancer subgroups for tailored therapy the metabolome of benign prostate tissues is influenced by nearby tumors of high grade. Front Mol Biosci. 2025;12:12\u20132025. https:\/\/doi.org\/10.3389\/fmolb.2025.1426949.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"9035_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/1078-0432.CCR-09-0103","volume":"16","author":"P Hammarsten","year":"2010","unstructured":"Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikstrom P, Egevad L, et al. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res. 2010;16(4):1245\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0103.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9035_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/00365599.2012.669791","volume":"46","author":"A Josefsson","year":"2012","unstructured":"Josefsson A, Wikstrom P, Egevad L, Granfors T, Karlberg L, Stattin P, et al. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand J Urol Nephrol. 2012;46(4):247\u201357. https:\/\/doi.org\/10.3109\/00365599.2012.669791.","journal-title":"Scand J Urol Nephrol"},{"issue":"8","key":"9035_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pros.20927","volume":"69","author":"P Wikstrom","year":"2009","unstructured":"Wikstrom P, Marusic J, Stattin P, Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate. 2009;69(8):799\u2013809. https:\/\/doi.org\/10.1002\/pros.20927.","journal-title":"Prostate"},{"issue":"1","key":"9035_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2407-5-45","volume":"5","author":"UR Chandran","year":"2005","unstructured":"Chandran UR, Dhir R, Ma CQ, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005;5(1):5. https:\/\/doi.org\/10.1186\/1471-2407-5-45.","journal-title":"BMC Cancer"},{"issue":"1","key":"9035_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat CommunicationsNat Commun. 2023;14(1):663. https:\/\/doi.org\/10.1038\/s41467-023-36325-2.","journal-title":"Nat CommunicationsNat Commun"},{"issue":"1","key":"9035_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ajpath.2012.03.043","volume":"181","author":"F Kosari","year":"2012","unstructured":"Kosari F, Cheville JC, Ida CM, Karnes RJ, Leontovich AA, Sebo TJ, et al. Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer. Am J Pathol. 2012;181(1):34\u201342. https:\/\/doi.org\/10.1016\/j.ajpath.2012.03.043.","journal-title":"Am J Pathol"},{"issue":"22","key":"9035_CR21","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1158\/1078-0432.CCR-10-0272","volume":"16","author":"MC Risk","year":"2010","unstructured":"Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, LeMeur N, et al. Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res. 2010;16(22):5414\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0272.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"9035_CR22","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.2004.05.158","volume":"22","author":"YP Yu","year":"2004","unstructured":"Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22(14):2790\u201399. https:\/\/doi.org\/10.1200\/JCO.2004.05.158.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9035_CR23","doi-asserted-by":"publisher","first-page":"10160","DOI":"10.1038\/s41467-025-65161-9","volume":"16","author":"S Krossa","year":"2025","unstructured":"Krossa S, Andersen MK, Sandholm EM, Wess M, Kiviaho A, Sharma A, et al. Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment. Nat CommunicationsNat Commun. 2025;16(1):10160. https:\/\/doi.org\/10.1038\/s41467-025-65161-9.","journal-title":"Nat CommunicationsNat Commun"},{"issue":"23","key":"9035_CR24","doi-asserted-by":"publisher","first-page":"33855","DOI":"10.18632\/oncotarget.8944","volume":"7","author":"C Magi-Galluzzi","year":"2016","unstructured":"Magi-Galluzzi C, Maddala T, Falzarano SM, Cherbavaz DB, Zhang N, Knezevic D, et al. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. Oncotarget. 2016;7(23):33855\u201365. https:\/\/doi.org\/10.18632\/oncotarget.8944.","journal-title":"Oncotarget"},{"key":"9035_CR25","doi-asserted-by":"publisher","first-page":"632571","DOI":"10.3389\/fonc.2021.632571","volume":"11","author":"R Zhou","year":"2021","unstructured":"Zhou R, Feng Y, Ye J, Han Z, Liang Y, Chen Q, et al. Prediction biochemical recurrence-free survival prostate cancer patients leveraging multiple gene expression profiles tumor microenvironment. Front Oncol. 2021;11:632571.","journal-title":"Front Oncol"},{"issue":"1","key":"9035_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41467-017-00460-4","volume":"8","author":"S Tyekucheva","year":"2017","unstructured":"Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat CommunicationsNat Commun. 2017;8(1):420. https:\/\/doi.org\/10.1038\/s41467-017-00460-4.","journal-title":"Nat CommunicationsNat Commun"},{"issue":"12","key":"9035_CR27","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","volume":"3","author":"SG Zhao","year":"2017","unstructured":"Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. JAMA Oncol. 2017;3(12):1663\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0751.","journal-title":"JAMA Oncol"},{"issue":"6","key":"9035_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","volume":"77","author":"JJ Tosoian","year":"2020","unstructured":"Tosoian JJ, Mamawala M, Epstein JI, Landis P, Macura KJ, Simopoulos DN, et al. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol. 2020;77(6):675\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2019.12.017.","journal-title":"Eur Urol"},{"issue":"1","key":"9035_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41597-025-04758-7","volume":"12","author":"E Chelebian","year":"2025","unstructured":"Chelebian E, Avenel C, Jaremo H, Andersson P, Wahlby C, Bergh A. A clinical prostate biopsy dataset with undetected cancer. Sci DataSci Data. 2025;12(1):423. https:\/\/doi.org\/10.1038\/s41597-025-04758-7.","journal-title":"Sci DataSci Data"},{"issue":"12","key":"9035_CR30","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1080\/0284186X.2023.2254480","volume":"62","author":"V Spyratou","year":"2023","unstructured":"Spyratou V, Freyhult E, Bergh A, Thellenberg-Karlsson C, Wikstrom P, Welen K, et al. Ki67 and prostate specific antigen are prognostic in metastatic hormone na\u00efve prostate cancer. Acta Oncol. 2023;62(12):1698\u2013706. https:\/\/doi.org\/10.1080\/0284186X.2023.2254480.","journal-title":"Acta Oncol"},{"issue":"2","key":"9035_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","volume":"4","author":"RA Irizarry","year":"2003","unstructured":"Irizarry RA. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249\u201364. https:\/\/doi.org\/10.1093\/biostatistics\/4.2.249.","journal-title":"Biostatistics"},{"issue":"19","key":"9035_CR32","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/bioinformatics\/btq431","volume":"26","author":"BS Carvalho","year":"2010","unstructured":"Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26(19):2363\u201367. https:\/\/doi.org\/10.1093\/bioinformatics\/btq431.","journal-title":"Bioinformatics"},{"issue":"8","key":"9035_CR33","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1021\/acs.jproteome.5b00354","volume":"14","author":"EA Thevenot","year":"2015","unstructured":"Thevenot EA, Roux A, Xu Y, Ezan E, Junot C. Analysis of the human adult urinary metabolome variations with age, Body Mass index, and gender by implementing a comprehensive Workflow for univariate and OPLS statistical analyses. J Proteome Res. 2015;14(8):3322\u201335. https:\/\/doi.org\/10.1021\/acs.jproteome.5b00354.","journal-title":"J Proteome Res"},{"key":"9035_CR34","doi-asserted-by":"publisher","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","DOI":"10.1093\/nar\/gkv007"},{"key":"9035_CR35","doi-asserted-by":"publisher","unstructured":"Korotkevich G, Sukhov V, Sergushichev A. Fast gene set enrichment analysis. bioRxiv. 2019;060012. https:\/\/doi.org\/10.1101\/060012.","DOI":"10.1101\/060012"},{"issue":"43","key":"9035_CR36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"9035_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"issue":"12","key":"9035_CR38","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739\u201340. https:\/\/doi.org\/10.1093\/bioinformatics\/btr260.","journal-title":"Bioinformatics"},{"issue":"5","key":"9035_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10585-025-10365-y","volume":"42","author":"S Halin Bergstrom","year":"2025","unstructured":"Halin Bergstrom S, Semenas J, Nordstrand A, Thysell E, Wanman J, Crnalic S, et al. Morphological heterogeneities in prostate cancer bone metastases are related to molecular subtypes and prognosis. Clin Exp Metastasis. 2025;42(5):49. https:\/\/doi.org\/10.1007\/s10585-025-10365-y.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"9035_CR40","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5.","journal-title":"Sci Rep"},{"key":"9035_CR41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3892\/ijo.2020.4980","volume":"56","author":"F Amirrad","year":"2020","unstructured":"Amirrad F, Pytak PA, Sadeghiani\u2011Pelar N, Nguyen JPT, Cauble EL, Jones AC, et al. Prostate field cancerization and exosomes: association between CD9, early growth response 1 and fatty acid synthase. Int J Oncol. 2020;56:957\u201368. https:\/\/doi.org\/10.3892\/ijo.2020.4980.","journal-title":"Int J Oncol"},{"issue":"1","key":"9035_CR42","doi-asserted-by":"publisher","first-page":"31805","DOI":"10.1038\/srep31805","volume":"6","author":"S Halin Bergstrom","year":"2016","unstructured":"Halin Bergstrom S, Hagglof C, Thysell E, Bergh A, Wikstrom P, Lundholm M. Extracellular vesicles from metastatic rat prostate tumors prime the normal prostate tissue to facilitate tumor growth. Sci Rep. 2016;6(1):31805. https:\/\/doi.org\/10.1038\/srep31805.","journal-title":"Sci Rep"},{"issue":"2","key":"9035_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2011.01.002","volume":"21","author":"H Peinado","year":"2011","unstructured":"Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011;21(2):139\u201346. https:\/\/doi.org\/10.1016\/j.semcancer.2011.01.002.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"9035_CR44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Sig Transduct Target Ther. 2024;9(1):236. https:\/\/doi.org\/10.1038\/s41392-024-01937-7.","journal-title":"Sig Transduct Target Ther"},{"issue":"7922","key":"9035_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-05023-2","volume":"608","author":"A Erickson","year":"2022","unstructured":"Erickson A, He M, Berglund E, Marklund M, Mirzazadeh R, Schultz N, et al. Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature. 2022;608(7922):360\u201367. https:\/\/doi.org\/10.1038\/s41586-022-05023-2.","journal-title":"Nature"},{"issue":"1","key":"9035_CR46","doi-asserted-by":"publisher","first-page":"7908","DOI":"10.1038\/s41598-022-12131-6","volume":"12","author":"S Halin Bergstrom","year":"2022","unstructured":"Halin Bergstrom S, Lundholm M, Nordstrand A, Bergh A. Rat prostate tumors induce DNA synthesis in remote organs. Sci Rep. 2022;12(1):7908. https:\/\/doi.org\/10.1038\/s41598-022-12131-6.","journal-title":"Sci Rep"},{"issue":"42","key":"9035_CR47","doi-asserted-by":"publisher","first-page":"17992","DOI":"10.1073\/pnas.1008260107","volume":"107","author":"CE Redon","year":"2010","unstructured":"Redon CE, Dickey JS, Nakamura AJ, Kareva IG, Naf D, Nowsheen S, et al. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc Natl Acad Sci U S A. 2010;107(42):17992\u201397. https:\/\/doi.org\/10.1073\/pnas.1008260107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9035_CR48","doi-asserted-by":"publisher","unstructured":"Dinges SS, Vandergrift LA, Wu S, Berker Y, Habbel P, Taupitz M, et al. Metabolomic prostate cancer fields in HRMAS MRS-profiled histologically benign tissue vary with cancer status and distance from cancer. NMR Biomed. 2019;32(10):e 4038. https:\/\/doi.org\/10.1002\/nbm.4038.","DOI":"10.1002\/nbm.4038"},{"key":"9035_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/BMI.S6794","volume":"6","author":"K Stenman","year":"2011","unstructured":"Stenman K, Stattin P, Stenlund H, Riklund K, Grobner G, Bergh A. H HRMAS NMR derived bio-markers related to tumor grade, tumor cell fraction, and cell proliferation in prostate tissue samples. Biomark Insights. 2011;6:39\u201347. https:\/\/doi.org\/10.4137\/BMI.S6794.","journal-title":"Biomark Insights"},{"issue":"1","key":"9035_CR50","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1038\/s41598-018-23177-w","volume":"8","author":"LA Vandergrift","year":"2018","unstructured":"Vandergrift LA, Decelle EA, Kurth J, Wu S, Fuss TL, DeFeo EM, et al. Metabolomic prediction of human prostate cancer aggressiveness: magnetic resonance spectroscopy of histologically benign tissue. Sci Rep. 2018;8(1):4997. https:\/\/doi.org\/10.1038\/s41598-018-23177-w.","journal-title":"Sci Rep"},{"issue":"3","key":"9035_CR51","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/pcan.2011.70","volume":"15","author":"R Dittrich","year":"2012","unstructured":"Dittrich R, Kurth J, Decelle EA, DeFeo EM, Taupitz M, Wu S, et al. Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer Prostatic Dis. 2012;15(3):278\u201382. https:\/\/doi.org\/10.1038\/pcan.2011.70.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"9035_CR52","doi-asserted-by":"publisher","unstructured":"Amiryousefi A, Wala J, Lin JR, Labadie BW, Atmakuri A, Maliga Z, et al. Spatially organized lymphocytic microenvironments in high grade primary prostate tumors. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.09.21.677465.","DOI":"10.1101\/2025.09.21.677465"},{"issue":"12","key":"9035_CR53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.celrep.2021.110132","volume":"37","author":"ZK Tuong","year":"2021","unstructured":"Tuong ZK, Loudon KW, Berry B, Richoz N, Jones J, Tan X, et al. Resolving the immune landscape of human prostate at a single-cell level in health and cancer. Cell Rep. 2021;37(12):37. https:\/\/doi.org\/10.1016\/j.celrep.2021.110132.","journal-title":"Cell Rep"},{"issue":"5","key":"9035_CR54","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jncc.2025.06.003","volume":"5","author":"Z Wang","year":"2025","unstructured":"Wang Z, Ge Q, Mo R, Lu J, Tian X, Anwaier A, et al. Spatial and maturity heterogeneity of tertiary lymphoid structures shapes immune microenvironment and progression in prostate cancer. J Natl Cancer Cent. 2025;5(5):501\u201314. https:\/\/doi.org\/10.1016\/j.jncc.2025.06.003.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"9035_CR55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/pros.23442","volume":"78","author":"S Davidsson","year":"2018","unstructured":"Davidsson S, Andren O, Ohlson AL, Carlsson J, Andersson SO, Giunchi F, et al. FOXP3 + regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. Prostate. 2018;78(1):40\u201347. https:\/\/doi.org\/10.1002\/pros.23442.","journal-title":"Prostate"},{"key":"9035_CR56","doi-asserted-by":"publisher","first-page":"1626708","DOI":"10.3389\/fimmu.2025.1626708","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Zhang L, Liu R, Xu C, Tang H, Zou Y, et al. CXCL12\/CXCR4 axis governs Treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer. Front Immunol. 2025;16:1626708. https:\/\/doi.org\/10.3389\/fimmu.2025.1626708.","journal-title":"Front Immunol"},{"issue":"1","key":"9035_CR57","doi-asserted-by":"publisher","first-page":"15651","DOI":"10.1038\/srep15651","volume":"5","author":"M Lundholm","year":"2015","unstructured":"Lundholm M, Hagglof C, Wikberg ML, Stattin P, Egevad L, Bergh A, et al. Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions. Sci Rep. 2015;5(1):15651. https:\/\/doi.org\/10.1038\/srep15651.","journal-title":"Sci Rep"},{"issue":"2","key":"9035_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1593\/neo.81338","volume":"11","author":"S Halin","year":"2009","unstructured":"Halin S, Rudolfsson SH, Van Rooijen N, Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia. 2009;11(2):177\u201386. https:\/\/doi.org\/10.1593\/neo.81338.","journal-title":"Neoplasia"},{"issue":"4","key":"9035_CR59","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.juro.2014.04.013","volume":"192","author":"AW Partin","year":"2014","unstructured":"Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014;192(4):1081\u201387. https:\/\/doi.org\/10.1016\/j.juro.2014.04.013.","journal-title":"J Urol"},{"issue":"12","key":"9035_CR60","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/pros.23191","volume":"76","author":"L Van Neste","year":"2016","unstructured":"Van Neste L, Partin AW, Stewart GD, Epstein JI, Harrison DJ, Van Criekinge W. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate. 2016;76(12):1078\u201387. https:\/\/doi.org\/10.1002\/pros.23191.","journal-title":"Prostate"},{"issue":"1","key":"9035_CR61","doi-asserted-by":"publisher","first-page":"30770","DOI":"10.1038\/s41598-025-15105-6","volume":"15","author":"E Chelebian","year":"2025","unstructured":"Chelebian E, Avenel C, Jaremo H, Andersson P, Bergh A, Wahlby C. Discovery of tumour indicating morphological changes in benign prostate biopsies through AI. Sci Rep. 2025;15(1):30770. https:\/\/doi.org\/10.1038\/s41598-025-15105-6.","journal-title":"Sci Rep"},{"issue":"12","key":"9035_CR62","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","volume":"391","author":"J Hugosson","year":"2024","unstructured":"Hugosson J, Godtman RA, Wallstrom J, Axcrona U, Bergh A, Egevad L, et al. Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med. 2024;391(12):1083\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2406050.","journal-title":"N Engl J Med"},{"issue":"3","key":"9035_CR63","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jmoldx.2015.12.006","volume":"18","author":"BS Knudsen","year":"2016","unstructured":"Knudsen BS, Kim HL, Erho N, Shin H, Alshalalfa M, Lam LLC, et al. Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens. J Mol Diagn. 2016;18(3):395\u2013406. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.12.006.","journal-title":"J Mol Diagn"},{"issue":"21","key":"9035_CR64","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1158\/1078-0432.CCR-18-1229","volume":"24","author":"D Iglesias-Gato","year":"2018","unstructured":"Iglesias-Gato D, Thysell E, Tyanova S, Crnalic S, Santos A, Lima TS, et al. The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications. Clin Cancer Res. 2018;24(21):5433\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1229.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-09035-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-09035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-09035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:07:27Z","timestamp":1791270447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-09035-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9035"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-09035-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the declaration of Helsinki and ethical approval was obtained from the local ethics committee in Ume\u00e5. Approval Dnr 03\/482; 2013\u201357-31\u2009M with amendments 2016\u201381-32\u2009M, 2017\u2013197-32\u2009M. All participants gave informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the submission. We confirm that the content of the manuscript has not been published or submitted for publication elsewhere.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1252"}}